Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 6.63B +249.8% |
| Revenue (ttm) | 51.48M -12.6% |
| Net Income | -315.00M |
| EPS | -3.55 |
| Shares Out | 82.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 407,642 |
| Open | 79.46 |
| Previous Close | 80.65 |
| Day's Range | 78.65 - 80.73 |
| 52-Week Range | 28.06 - 103.00 |
| Beta | 2.06 |
| Analysts | Strong Buy |
| Price Target | 118.27 (+46.72%) |
| Earnings Date | Apr 30, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $118.27, which is an increase of 46.72% from the latest price.
News
Kymera Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
KT-621 phase IIb studies in atopic dermatitis and asthma are progressing on schedule, with strong enthusiasm and robust safety data supporting advancement. The pipeline includes promising IRF5 and IRAK4 degraders, with lupus prioritized for proof-of-concept and broader indications under consideration.
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases
Kymera Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Management highlighted progress in targeted protein degradation, focusing on immunology with KT-621 in phase II trials for atopic dermatitis and asthma, and IRF5 in early clinical studies. Differentiation is based on sustained target degradation, with large market opportunities in both adult and pediatric populations. Data readouts for key programs are expected in the next 12–24 months.
Kymera Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Edward Nash initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $106 price target
Kymera Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $106 price target The firm views Kymera as one of the “more cutting-edge technology companies” developing drugs within…
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models
Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Kymera Therapeutics (KYMR) to $119 from $123 and keeps an Overweight rating on the shares. Kymera Therapeutics highlighted conti...
Kymera Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong pipeline progress, with KT-621 advancing in AD and asthma and KT-579 entering phase I. Financially, $34.4M in revenue was recognized, with a $1.55B cash runway into 2029. Gilead exercised its KT-200 option, and key clinical data readouts are expected in 2026–2027.
Kymera Therapeutics Earnings release: Q1 2026
Kymera Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Kymera Therapeutics Quarterly report: Q1 2026
Kymera Therapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.
Kymera Therapeutics Slides: Q1 2026
Kymera Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)
Reports Q1 revenue $34.37M, consensus $8.23M. “As we continue to advance KT-621 and KT-579 through clinical development, our focus remains on disciplined execution and delivering on multiple important...
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K...
Kymera Therapeutics Proxy statement: Proxy filing
Kymera Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Kymera Therapeutics Proxy statement: Proxy filing
Kymera Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...
FDA grants fast track designation to Kymera Therapeutics KT-621
Kymera Therapeutics (KYMR) announced that the FDA has granted fast track designation to KT-621, its oral STAT6 degrader, for the treatment of moderate to severe eosinophilic asthma. KT-621 is currentl...
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de...
Kymera Therapeutics announces Gilead option exercise to license KT-200
Kymera Therapeutics (KYMR) announced that Gilead Sciences (GILD) has exercised its option to exclusively license KT-200, oral CDK2 molecular glue degrader development candidate discovered and characte...
Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
Kymera Therapeutics (KYMR) announced that the positive results from the BroADen Phase 1b atopic dermatitis, AD, clinical trial of KT-621, its first-in-class, oral STAT6 degrader, were featured in a la...
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile
Kymera Therapeutics assumed with a Buy at Jefferies
Jefferies analyst Faisal Kurshid assumed coverage of Kymera Therapeutics (KYMR) with a Buy rating and a price target of $110, down from $122. STAT6 degrader KT-621 holds the promise of…
Kymera Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing a pipeline of oral immunology therapies, with STAT6 and IRF5 as lead programs targeting large unmet needs. Phase II trials in atopic dermatitis and asthma are underway, and the company is well-funded to pursue broad clinical development independently.
Kymera Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The conference highlighted advances in targeted protein degradation, with KT-621 showing robust efficacy and safety in early trials for AD and asthma, and strong interest from the medical community. IRF5 is prioritized for lupus, with additional pipeline programs expected to be announced later this year.